Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
Desroy, N., Housseman, C., Bock, X., Joncour, A., Bienvenu, N., Cherel, L., Labeguere, V., Rondet, E., Peixoto, C., Grassot, J.M., Picolet, O., Annoot, D., Triballeau, N., Monjardet, A., Wakselman, E., Roncoroni, V., Le Tallec, S., Blanque, R., Cottereaux, C., Vandervoort, N., Christophe, T., Mollat, P., Lamers, M., Auberval, M., Hrvacic, B., Ralic, J., Oste, L., van der Aar, E., Brys, R., Heckmann, B.
J. Med. Chem.
